X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.
Lead Product(s): Granisetron
Therapeutic Area: Gastroenterology Product Name: Sancuso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Verity Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 09, 2022
Details:
Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO (Granisetron) and will assume full commercial responsibility for the product - including its marketing, promotion, distribution, manufacturing and medical support activities.
Lead Product(s): Granisetron
Therapeutic Area: Gastroenterology Product Name: Sancuso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cumberland Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
